FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/02/2026
Back to search
Official data from USPTO
RECIPHARM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RECIPHARM
ST13
US500000079401677Class
5, 42
Filing
79401677
Registration
7910168
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
04/03/2026
Trademark type
Word
Nice classes
5, 42
Filing date
06/03/2024
Registration date
08/26/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/26/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
64
Owner location
SE
Examiner
HERR, JENNA FRANCES
Law office
L10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Recipharm AB
Representatives
Robert J. Kenney Willcox & Savage, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medical preparations for treating diseases and genetic disorders in the fields of haematologyoncologycardiologymetabolic diseases and genetic disorders; sanitary preparations for medical purposes; dietetic foods and dietetic substances adapted for medical or veterinary use; infant formula; dietary supplements for human beings and animals; medical plastersmaterials for dressing in the nature of bandages; teeth filling material; dental wax; disinfectants; vermin destroying preparations; antifungal preparations; herbicides
Class 42
Scientific and technological servicesresearch and design in the field of development and manufacturing of biopharmaceutical and pharmaceutical products and technologies; medical research laboratory services. Scientific laboratory services; development of medical products; industrial analysis research in the field of development and manufacturing of biopharmaceutical and pharmaceutical products; industrial research and industrial design in the field of biopharmaceutical and pharmaceutical products
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/14/2026
FIMP
FINAL DISPOSITION PROCESSED
03/13/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/22/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/07/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/26/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/26/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/26/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/10/2025
PUBO
PUBLISHED FOR OPPOSITION
06/10/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/08/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/28/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/28/2025
RFNT
REFUSAL PROCESSED BY IB
02/01/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/16/2025
RFRR
REFUSAL PROCESSED BY MPU
01/16/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/21/2024
CNRT
NON-FINAL ACTION WRITTEN
12/20/2024
DOCK
ASSIGNED TO EXAMINER
12/14/2024
MAFR
APPLICATION FILING RECEIPT MAILED
08/16/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/16/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2024
Continuous trademark protection
Get notified about every new filing that threatens RECIPHARM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.